Smallcap pharma stock hits over 8% upper circuit after securing marketing nod for chemotherapy drugs; do you own?
Venus Remedies Share Price Today: Shares of pharmaceutical major Venus Remedies were locked in at over 8 per cent upper circuit at ₹407.60 apiece on the BSE, near its 52-week mark of ₹419.05 on Thursday, December 21. The rally was driven after the pharma company announced that it has secured marketing authorisations for three variants of Docetaxel in Israel and for Cytarabine 100 mg in Colombia. These drugs are typically used in oncology and chemotherapy to treat cancer patients.
‘’Venus Remedies, a global leader in pharmaceutical innovation, is excited to announce dual achievements in securing marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify our commitment to advancing healthcare solutions globally,” said the company in a regulatory filing to the stock exchanges.
MORE TO COME
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it’s all here, just a click away! Login Now!
Download The Mint News App to get Daily Market Updates.
Published: 21 Dec 2023, 05:38 PM IST
